---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-044025"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:49:04.879817+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx reports positive 3-year Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia

## Summary
- 62% of patients had ≥10-point XQ improvement at 36 months; average 17-point improvement maintained from 12 months.
- Unstimulated saliva flow normalized to average 0.36 mL/min at 12 months, maintained at 0.34 mL/min at 36 months.
- No dose-limiting toxicity or treatment-related serious adverse events; well tolerated at all doses.
- Company estimates peak global revenue potential of $3.7B, U.S. peak of $2.0B, targeting ~165,000 U.S. patients.

## SEC filing metadata
- accession: 0001104659-26-044025
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000110465926044025/0001104659-26-044025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000110465926044025/mgtx-20260416x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-044025
- JSON: https://secwatch.observer/filing/0001104659-26-044025.json
- Plain text: https://secwatch.observer/filing/0001104659-26-044025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.